Research programme: gap junction protein mediated hearing loss gene therapies - Akouos
Alternative Names: GJB2 gene therapies - Akouos; Hearing loss gene therapies - AkouosLatest Information Update: 05 Dec 2022
At a glance
- Originator Akouos
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Hearing loss
Most Recent Events
- 01 Dec 2022 Akouos has been acquired by Eli Lilly and Company
- 12 Aug 2021 Early research in Hearing loss in USA (Parenteral) prior to August 2021 (80G9332874)
- 30 Nov 2017 Lonza and Massachusetts Eye and Ear exclusively license ancestral adeno-associated viral vectors (Anc-AAV) gene therapy platform to Akouos